Immunogenicity and safety of the quadrivalent human papillomavirus vaccine in Chinese females aged 9 to 26 years: A phase 3, open-label, immunobridging study-Reference-Cited by-同舟云学术

Immunogenicity and safety of the quadrivalent human papillomavirus vaccine in Chinese females aged 9 to 26 years: A phase 3, open-label, immunobridging study

Published:2021-01 Issue:4 Volume:39 Page:760-766
ISSN:0264-410X
Container-title:Vaccine
language:en
Short-container-title:Vaccine

Author:

Huang Zhuhang,He Jianfeng,Su Jiali,Ou Zhiqiang,Liu Guixiu,Fu Rong,Shou Qiong,Zheng Minghuan,Group Thomas,Luxembourg Alain,Liao Xueyan,Zhang Jikai

Funder

Merck Sharp and Dohme

Publisher

Elsevier BV

Subject

Infectious Diseases,Public Health, Environmental and Occupational Health,General Veterinary,General Immunology and Microbiology,Molecular Medicine

Reference29 articles.

1. Epidemiology and burden of HPV-related disease;Serrano;Best Pract Res Clin Obstet Gynaecol,2018

2. Lacey CJN, Lowndes CM, Shah KV. Chapter 4: Burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease. Vaccine 2006;24(Supplement 3):S35-S41.

3. Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis;de Martel;Lancet Glob Health,2020

4. 9-Valent human papillomavirus vaccine: a review of the clinical development program;Luxembourg;Expert Rev Vaccines,2017

5. Yujie X. China approves production of first domestic HPV vaccine, https://www.sixthtone.com/news/1005031/china-approves-production-of-first-domestic-hpv-vaccine; 2020 [accessed 02 Jan 2020].

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunogenicity and safety of the 9-valent human papillomavirus vaccine in Chinese females 9–45 years of age: A phase 3 open-label study;Vaccine;2022-05

2. An Immunobridging Study to Evaluate the Neutralizing Antibody Titer in Adults Immunized with Two Doses of Either ChAdOx1-nCov-19 (AstraZeneca) or MVC-COV1901;Vaccines;2022-04-21